title: Structural insights into adrenergic receptor function and pharmacology.
abstract: It has been over 50years since Sir James Black developed the first beta adrenergic receptor (βAR) blocker to treat heart disease. At that time, the concept of cell surface receptors was relatively new and not widely accepted, and most of the tools currently used to characterize plasma membrane receptors had not been developed. There has been remarkable progress in receptor biology since then, including the development of radioligand binding assays, the biochemical characterization of receptors as discrete membrane proteins, and the cloning of the first G-protein-coupled receptors (GPCRs), which led to the identification of other members of the large family of GPCRs. More recently, progress in GPCR structural biology has led to insights into the three-dimensional structures of βARs in both active and inactive states. Despite all of this progress, the process of developing a drug for a particular GPCR target has become more complex, time-consuming and expensive.
authors.affiliation: Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94306, USA. kobilka@stanford.edu
authors.forename: Brian K
authors.initials: BK
authors.lastname: Kobilka
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D016503:Drug Delivery Systems; D015195:Drug Design; D006331:Heart Diseases / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D021621:Imaging, Three-Dimensional; D011943:Receptors, Adrenergic, beta / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000319:Adrenergic beta-Antagonists; D011943:Receptors, Adrenergic, beta; D043562:Receptors, G-Protein-Coupled